Hormone replacement after gynaecological cancer

Maturitas

Volumn 65, Issue 3, 2010, Pages 190-197

  Singh, Piksi ^a   Oehler, Martin K ^b,c  

^a ROYAL HOBART HOSPITAL   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Endometrial cancer; Gynaecological cancer; Hormone replacement therapy (HRT); Menopausal symptoms; Oestrogen treatment; Ovarian cancer; Uterine sarcoma

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; DEMOGRAPHY; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; MENOPAUSAL SYNDROME; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERUS SARCOMA; VAGINA CANCER;

ESTROGEN REPLACEMENT THERAPY; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MENOPAUSE, PREMATURE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS;

EID: 76349101148     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.11.017     Document Type: Review

References (69)

1. Jemal A., Siegel R., Ward E., et al. Cancer Statistic. CA Cancer J. Clin. 59 (2009) 225-249
2. MacLennan A.H., Lester S., and Moore V. Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 4 (2001) 58-74
3. Benshushan A., Rojansky N., Chaviv M., et al. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy. Climacteric 25 (2009) 1-6
4. Parker H., Broder M.S., Chang E., et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurse's health study. Obstet. Gynecol. 113 (2009) 1027-1037
5. Hlatky M.A., Boothroyd D., Vittinghoff E., Sharp P., and Whooley M.A. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 287 (2002) 591-597
6. Brunner R.L., Gass M., Aragaki A., et al. Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from Women's Health Initiative. Randomized clinical trial. Arch. Intern. Med. 165 (2005) 1976-1986
7. Ditkoff E.C., Crary W.G., Cristo M., and Lobo R.A. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet. Gynecol. 78 (1991) 991-995
8. Soares C.N., Almeida O.P., Joffe H., and Cohen L.S. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double blind, randomised, placebo-controlled trial. Arch. Gen. Psychiatry 58 (2001) 529-534
9. Wren B. Hormonal therapy and genital tract cancer. Curr. Opin. Obstet. Gynecol. 8 (1996) 38-41
10. Persson I., Yuen J., Bergkvist L., and Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long term follow-up of a Swedish cohort. Int. J. Cancer 67 (1996) 327-332
11. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Writing group for the Women's Health Initiative investigators. Risks and Benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288 (2002) 321-333
12. Gallup D.G., and Stock R.J. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet. Gynecol. 64 (1984) 417-420
13. DiSaia P.J., and Creasman W.T. Clinical gynaecologic oncology. 7th ed. (2007), Mosby, Philadelphia Adenocarcinoma of the uterus, Chapter 5
14. Grady D., Gebrestsadik T., Kerlikowske K., Ernstr V., and Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 85 (1995) 304-313
15. Weiderpass E., Adami H.O., Baron J.A., et al. Risk of endometrial cancer following estrogen replacement therapy with and without progestin. J. Natl. Cancer Inst. 91 (1991) 1131-1137
16. Creasman W.T., Henderson D., Hinshaw W., and Clarke-Pearson D.L. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet. Gynecol. 67 (1986) 326-330
17. Byrant G.W. Administration of estrogens to patients with a previous diagnosis of endometrial adenocarcinoma. South Med. J. 83 (1990) 725-726
18. Baker D.D. Estrogen replacement therapy in patient with previous endometrial carcinoma. Compr. Ther. 16 (1990) 28-35
19. Lee R.B., Burke T.W., and Park R.C. Estrogen replacement therapy following treatment for stage 1 endometrial carcinoma. Gynecol. Oncol. 36 (1990) 189-191
20. Chapman J.A., DiSaia P.J., Osann K., Roth P.D., Gillotte D.L., and Berman M.L. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am. J. Obstet. Gynecol. 175 (1996) 1195-1200
21. Suriano K.A., McHale M., McLaren C.E., Li K.T., Re A., and DiSaia P.J. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet. Gynecol. 97 (2001) 555-560
22. Ayhan A., Taskiran C., Simsek S., and Sever A. Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors?. Int. J. Gynecol. Cancer 16 (2006) 805-808
23. Barakat R.R., Brundy B.N., Spirtos N.M., Bell J., and Mannel R.S. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II Endometrial cancer: a Gynaecologic Oncology Group study. J. Clin. Oncol. 24 (2006) 587-592
24. Ursic-Vrscaj M. Hormone replacement therapy after uterine leiomyosarcoma treatment. Case reports. Eur. J. Gynaecol. Oncol. 20 (1999) 379-382
25. Tavassoli F.A., and Devilee P. Tumors of the Breast and Female Genital Tract. Pathology and Genetics. World Health Organization Classification of Tumors (2003), IARC, Lyon
26. Karabakhtsian R., Heller D.S., Singhal P., and Sama J. Malignant mixed mesodermal tumor in a young woman with polycystic ovary syndrome. A case report. J. Reprod. Med. 47 (2002) 946-948
27. Reich O., and Regauer S. Hormonal therapy of endometrial stromal sarcoma. Curr. Opin. Oncol. 19 (2007) 347-352
28. Pink D., Lindner T., Mrozek A., et al. Harm or benefit of hormone replacement in metastatic low-grade endometrial stromal sarcoma: Single centre experience with 10 cases and review of literature. Gynecol. Oncol. 101 (2006) 464-469
29. Spano J.P., Soria J.C., Kambouchner M., et al. Long-term survival of patients given hormone therapy for metastatic endometrial stromal sarcoma. Case Report. Med. Oncol. 20 (2003) 87-93
30. Controversial issues in climacteric medicine II: hormone replacement therapy and cancer-position paper. International Menopause Society Expert Workshop. Opera del Duomo, Pisa, Italy, June 9-12 (2001)
31. Surveillance, Epidemiology, and End Results (SEER) Program. SEER (Stat Database: Incidence-Seer 9 Regs Public use, Nov 2007 Sub (1973-2005)) - Linked to county attributes - Total US, 1969-2005 counties. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2008. Released April 2008 based on the November 2007 submission. Available at www.seer.cancer.gov.
32. In: Reis L.A.G., Melbert D., Krapcho M., et al. (Eds). SEER Cancer statistics Review, 1975-2005 (2008), NCI, Bethesda, MD. http://www.seer.cancer.gov/csr/1975_2005 Available at: www.seer.cancer.gov/csr/1975_2005
33. Heaps J.M., Nieberg R.K., and Berek J.S. Malignant neoplasms arising in endometriosis. Obstet. Gynecol. 75 (1990) 1023-1028
34. McMeekin D.S., Burger R.A., Manetta A., DiSaia P., and Berman M.L. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol. Oncol. 59 (1995) 81-86
35. Surface epithelial-stromal tumors of the ovary. In: Russell P., and Kurman R.J. (Eds). Blaustein's pathology of the female genital tract (1994), Springer Verlag, New York 705
36. Gotlieb W.H., Chetrit A., Menczer J., et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol. Oncol. 97 (2005) 780-783
37. Wang P.H., and Chang C. Androgens and ovarian cancers. Eur. J. Gynecol. Oncol. 25 (2004) 157-163
38. Coughlin S.S., Giustozzi A., Smith S.J., and Lee N.C. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J. Clin. Epidemiol. 53 (2000) 367-375
39. Garg P.P., Kerlikowske K., Subak L., and Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet. Gynecol. 92 (1998) 472-479
40. Eeles R.A., Tan S., Wiltshaw E., et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ 302 (1991) 259-262
41. Guidozzi F., and Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomised control trial. Cancer 86 (1999) 1013-1018
42. Bebar S., and Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur. J. Gynecol. Oncol. 21 (2000) 192-196
43. Ursic-Vrscaj M., Bebar S., and Zakelj M.P. Hormone replacement therapy after invasive ovarian cystadenocarcinoma treatment: the effect on survival. Menopause 8 (2001) 70-75
44. Mascarenhas C., Lambe M., Bellocco R., et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int. J. Cancer 119 (2006) 2907-2915
45. Kotsopoulos J., Lubinski J., Neuhausen S.L., et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol. Oncol. 100 (2006) 83-88
46. Eltabbakh G.H., Piver M.S., Hempling R.E., Recio F.O., and Aiduk C. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer. Gynecol. Oncol. 66 (1997) 103-107
47. Zalel Y., Piura B., Elchalal U., Czernobilsky B., Antebi S., and Dgani R. Diagnosis and management of malignant germ cell ovarian tumors in young females. Int. J. Gynaecol. Obstet. 55 (1996) 1-10
48. Billmire D., Vinocur C., Rescorla F., et al. Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study. J. Pediatr. Surg. 39 (2004) 424-429 discussion 424-29
49. Gershenson D.M., Miller A.M., Champion V.L., et al. Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25 (2007) 2792-2797
50. Tabata M., Ichnoe K., Sakuragi N., Shiina Y., Yamaguchi T., and Mabuchi Y. Incidence of ovarian metastasis in patients with cancer of uterine cervix. Gynecol. Oncol. 28 (1987) 255-261
51. Shimada M., Kigawa J., Nishimura R., et al. Ovarian metastasis in cancer of the uterine cervix. Gynecol. Oncol. 101 (2006) 234-237
52. Natsume N., Aoki Y., Kase H., Kashima K., Sugaya S., and Tanaka K. Ovarian metastasis in stage 1 B and 11 cervical adenocarcinoma. Gynecol. Oncol. 74 (1999) 255-258
53. Ash P. The influence of radiation on fertility in man. Br. J. Radiol. 53 (1980) 271-278
54. Van Eijkeren M.A., Van Der Wijk I., El Sharouni S.Y., and Heintz A.P. Benefits and side effects of lateral ovarian transposition (LOT) performed during radical hysterectomy and pelvic lymphadenectomy for early stage cervical cancer. Int. J. Gynecol. Cancer 9 (1999) 396-400
55. Brand A.H., Bull C.A., and Cakir B. Vaginal stenosis in patients treated with radiotherapy for carcinoma of the cervix. Int. J. Gynecol. Cancer 16 (2006) 288-293
56. Ferenczy A., Gelfand M.M., Franco E., and Mansour N. Human papillomavirus infection in post menopausal women with and without hormone therapy. Obstet. Gynecol. 90 (1997) 7-11
57. Parazzini F., La Vecchia C., Negri E., et al. Case-control study of oestrogen replacement therapy and risk of cervical cancer. BMJ 315 (1997) 85-88
58. Smith J.S., Green J., Berrington de Gonzalez A., et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361 (2003) 1159-1167
59. Auborn K.J., Woodworth C., DiPaolo J.A., and Bradlow H.L. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int. J. Cancer 49 (1991) 867-869
60. Lacey J.V., Brinton L.A., Barnes W.A., et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol. Oncol. 77 (2000) 149-154
61. Ploch E. Hormone replacement therapy in patients after cervical cancer treatment. Gynecol. Oncol. 26 (1987) 169-177
62. Sheehan J.F., Schmitz H.E., and Towne J. Changes in the uterus after eradication of endometrial adenocarcinoma by radiotherapy. Arch. Pathol. 39 (1943) 237-245
63. Habeshaw T., and Pinion S.B. The incidence of persistent functioning endometrial tissue following successful radiotherapy for cervical carcinoma. Int. J. Gynecol. Cancer 2 (1992) 332-335
64. Messing M.J., and Gallup D.G. Carcinoma of vulva in young women. Obstet. Gynecol. 86 (1995) 51-54
65. Madsen B.S., Jensen H.L., Van den Brule A.J., Wohlfahrt J., and Frisch M. Risk factors for invasive squamous cell carcinoma of the vulva and vagina-population-based case-control study in Denmark. Int. J. Cancer 122 (2008) 2827-2834
66. Sherman K.J., Daling J.R., McKnight B., and Chu J. Hormonal factors in vulval cancer. A case-control study. J. Reprod. Med. 39 (1994) 857-861
67. Creasman W.T., Phillips J.L., and Menck H.R. The National Cancer Data Base report on cancer of the vagina. Cancer 83 (1998) 1033-1040
68. Melnick S., Cole P., Anderson D., and Herbst A. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. An update. N. Engl. J. Med. 316 (1987) 514-516
69. Rees M. Gynaecological oncology perspective on management of the menopause. Eur. J. Surg. Oncol. 32 (2006) 892-897